

# Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

## SK-MEL-3

RRID:CVCL\_0550

Type: Cell Line

### Proper Citation

RRID:CVCL\_0550

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0550](https://web.expasy.org/cellosaurus/CVCL_0550)

**Proper Citation:** RRID:CVCL\_0550

**Description:** Cell line SK-MEL-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Cutaneous melanoma

**Defining Citation:** [PMID:327080](#), [PMID:833871](#), [PMID:3518877](#), [PMID:6220172](#), [PMID:8755562](#), [PMID:11668190](#), [PMID:12068308](#), [PMID:17260012](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23285177](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

**Comments:** Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** SK-MEL-3

**Synonyms:** SK-Mel-3, Sk-mel-3, SK-MEL3, SK-Mel3, SKMEL3

**Cross References:** BTO:BTO\_0002132, CLO:CLO\_0009044, EFO:EFO\_0002333, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-69, BioSample:SAMN03472882, BioSample:SAMN10988234, cancercellines:CVCL\_0550,

CancerTools:161918, Cell\_Model\_Passport:SIDM01105, ChEMBL-Cells:ChEMBL3307449, ChEMBL-Targets:ChEMBL614920, Cosmic:687443, Cosmic:874445, Cosmic:888063, Cosmic:909724, Cosmic:1022286, Cosmic:1047688, Cosmic:1459671, Cosmic:1995636, Cosmic:2159449, Cosmic-CLP:909724, DepMap:ACH-000423, DSMZ:ACC-321, DSMZCellDive:ACC-321, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:909724, GEO:GSM156045, GEO:GSM827519, GEO:GSM887588, GEO:GSM888671, GEO:GSM1670440, IARC\_TP53:26114, IGRhCellID:SKMEL3, KCLB:30069, LiGeA:CCLE\_928, LINCX\_LDP:LCL-1266, NCBI\_Iran:C458, PharmacDB:SKMEL3\_1397\_2019, PRIDE:PXD022992, PRIDE:PXD030304, Progenetix:CVCL\_0550, PubChem\_Cell\_line:CVCL\_0550, Wikidata:Q54954057

**ID:** CVCL\_0550

**Record Creation Time:** 20220427T221546+0000

**Record Last Update:** 20260904T015655+0000

---

## Ratings and Alerts

No rating or validation information has been found for SK-MEL-3.

No alerts have been found for SK-MEL-3.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 11 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

D'Ambrosio M, et al. (2026) Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability. *Nature cell biology*, 28(5), 915.

Chang J, et al. (2025) Antagonistic roles for MITF and TFE3 in melanoma plasticity. *Cell reports*, 44(4), 115474.

Saamarthy K, et al. (2025) An optimised Bcl-3 inhibitor for melanoma treatment. *British journal of pharmacology*, 182(11), 2426.

Gadal S, et al. (2025) Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. *Cancer research*, 85(9), 1611.

Xu Y, et al. (2024) BRAF-induced EHF expression affects TERT in aggressive papillary thyroid cancer. *The Journal of clinical endocrinology and metabolism*.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Takaki EO, et al. (2024) A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(16), 3603.

Dolton G, et al. (2023) Targeting of multiple tumor-associated antigens by individual T??cell receptors during successful cancer immunotherapy. *Cell*, 186(16), 3333.

Tagore M, et al. (2023) GABA Regulates Electrical Activity and Tumor Initiation in Melanoma. *Cancer discovery*, 13(10), 2270.

Jahid S, et al. (2022) Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer. *Cell reports*, 39(1), 110641.

Deng W, et al. (2019) WNT1-inducible signaling pathway protein 1 (WISP1/CCN4) stimulates melanoma invasion and metastasis by promoting the epithelial-mesenchymal transition. *The Journal of biological chemistry*, 294(14), 5261.